Mårten Fernö
21 – 30 of 258
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
- Contribution to journal › Article
- 2019
-
Mark
Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer
- Contribution to journal › Article
-
Mark
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
- Contribution to journal › Article
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
- Contribution to journal › Article
-
Mark
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
- Contribution to journal › Article
-
Mark
Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes : A Long-Term Follow-Up of the SweBCG91RT Randomized Trial
- Contribution to journal › Article
-
Mark
Refinement of breast cancer molecular classification by miRNA expression profiles
- Contribution to journal › Article
- 2018
-
Mark
Immune gene expression and response to chemotherapy in advanced breast cancer
- Contribution to journal › Article
-
Mark
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
- Contribution to journal › Article
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
- Contribution to journal › Article
